(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
Live Chart Being Loaded With Signals
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment...
Stats | |
---|---|
आज की मात्रा | 9 800.00 |
औसत मात्रा | 22 419.00 |
बाजार मूल्य | 69.82B |
EPS | $20.86 ( 2023-10-31 ) |
अगली कमाई की तारीख | ( $0.000450 ) 2024-06-16 |
Last Dividend | $0.113 ( 2023-03-30 ) |
Next Dividend | $0 ( N/A ) |
P/E | 55.17 |
ATR14 | $0 (0.00%) |
Daiichi Sankyo Company, सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध |
---|
10 सबसे अधिक नकारात्मक सहसंबंध |
---|
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
Daiichi Sankyo Company, वित्तीय
Annual | 2024 |
राजस्व: | $1 601.69B |
सकल लाभ: | $1 186.37B (74.07 %) |
EPS: | $104.69 |
FY | 2024 |
राजस्व: | $1 601.69B |
सकल लाभ: | $1 186.37B (74.07 %) |
EPS: | $104.69 |
FY | 2023 |
राजस्व: | $1 278.48B |
सकल लाभ: | $914.95B (71.57 %) |
EPS: | $56.96 |
FY | 2022 |
राजस्व: | $1 044.89B |
सकल लाभ: | $682.09B (65.28 %) |
EPS: | $34.94 |
Financial Reports:
No articles found.
Daiichi Sankyo Company, Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.0940 (N/A) |
$0 (N/A) |
$0.113 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0980 | 2014-03-27 |
Last Dividend | $0.113 | 2023-03-30 |
Next Dividend | $0 | N/A |
Payout Date | 2011-12-01 | |
Next Payout Date | N/A | |
# dividends | 18 | -- |
Total Paid Out | $1.801 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.35 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.29 | |
Div. Directional Score | 8.89 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSMMY | Ex Dividend Junior | 2023-10-12 | Semi-Annually | 0 | 0.00% | |
EBRPY | Ex Dividend Knight | 2023-06-28 | Quarterly | 0 | 0.00% | |
VIAAY | Ex Dividend Junior | 2023-06-12 | Sporadic | 0 | 0.00% | |
KIGRY | Ex Dividend Junior | 2023-05-18 | Annually | 0 | 0.00% | |
BTSDF | No Dividend Player | 2023-09-05 | Annually | 0 | 0.00% | |
SBNC | Ex Dividend Junior | 2023-08-31 | Quarterly | 0 | 0.00% | |
FINMY | Ex Dividend Junior | 2023-05-22 | Sporadic | 0 | 0.00% | |
YZCAY | Ex Dividend Junior | 2023-07-03 | Annually | 0 | 0.00% | |
MHGU | Ex Dividend Junior | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
CLPHY | Ex Dividend Knight | 2023-09-01 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.125 | 1.500 | 7.49 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0580 | 1.200 | 8.07 | 9.68 | [0 - 0.3] |
returnOnEquityTTM | 0.125 | 1.500 | 9.72 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.335 | -1.000 | 6.65 | -6.65 | [0 - 1] |
currentRatioTTM | 3.01 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 1.522 | 0.800 | 5.75 | 4.60 | [0.8 - 2.5] |
cashRatioTTM | 0.895 | 1.500 | 6.14 | 9.21 | [0.2 - 2] |
debtRatioTTM | 0.0294 | -1.500 | 9.51 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 10.14 | 1.000 | 7.36 | 7.36 | [3 - 30] |
operatingCashFlowPerShareTTM | 312.31 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 248.32 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0603 | -1.500 | 9.76 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.741 | 1.000 | 0.988 | 0.988 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.115 | 1.000 | 9.70 | 9.70 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 5.89 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.463 | 0.800 | -0.248 | -0.199 | [0.5 - 2] |
Total Score | 12.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 53.23 | 1.000 | 4.72 | 0 | [1 - 100] |
returnOnEquityTTM | 0.125 | 2.50 | 9.82 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 248.32 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.00560 | 1.500 | 9.86 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 312.31 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.335 | 1.500 | 6.65 | -6.65 | [0 - 1] |
pegRatioTTM | 0.00552 | 1.500 | -3.30 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.374 | 1.000 | 3.15 | 0 | [0.1 - 0.5] |
Total Score | 5.29 |
Daiichi Sankyo Company,
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं